Research programme - RSPO-LGR antibody therapeutics - OncoMed

Drug Profile

Research programme - RSPO-LGR antibody therapeutics - OncoMed

Alternative Names: anti RSPO3; Anti-RSPO-LGR antibodies - OncoMed

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoMed Pharmaceuticals
  • Class Antibodies
  • Mechanism of Action G protein-coupled receptor antagonists; Stem cell inhibitors; Thrombospondin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA
  • 03 Dec 2013 OncoMed Pharmaceuticals and Celgene enter into a collaboration to jointly develop and commercialise up to six OncoMed anti-cancer stem cell product candidates, including up to four programmes targeting either the RSPO-LGR pathway or an undisclosed pathway
  • 09 Oct 2013 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top